AbbVie wins EC nod for new Rinvoq indication
The European Commission (EC) has granted marketing authorization to Rinvoq (upadacitinib; 15mg, once daily), from US pharma major AbbVie (NYSE: ABBV), for the treatment of giant cell arteritis (GCA) in adult patients.
AbbVie noted that Rinvoq is the first and only oral JAK inhibitor approved in the European Union (EU), as well as Iceland, Liechtenstein and Norway, for the treatment of adult patients with GCA, and marks the drug's eighth approved indication in the EU.
With global sales of nearly $6 billion in 2024, Rinvoq remains a key driver of AbbVie’s immunology portfolio growth, alongside the interleukin (IL)23 inhibitor Skyrizi (risankizumab) which has now overtaken the firm’s Humira (adalimumab) last year as the company’s top-selling drug but now facing generic competition.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
More on this story...
Today's issue
Company Spotlight
More Features in Pharmaceutical
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze